Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 18Vincristine 13Filgrastim 13Doxorubicin 13Carboplatin 13Etoposide 12Granulocyte Colony-Stimulating Factor 10Isotretinoin 9Cisplatin 9Topotecan 8Peripheral Blood Stem Cell Transplantation 8sargramostim 7Melphalan 7Radiotherapy 6etoposide phosphate 5Thiotepa 5Polymerase Chain Reaction 5Platinum 5Magnetic Resonance Spectroscopy 4Irinotecan 4Immunohistochemistry 4Gene Expression Profiling 4Colony-Stimulating Factors 41,2-diaminocyclohexaneplatinum II citrate 4lorukafusp alfa 3dinutuximab 3Temozolomide 3Stem Cell Transplantation 3Specimen Handling 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neuroblastoma × lorlatinib × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡